On July 21, the FDA approved Verrica Pharmaceuticals’ topical molluscum drug, Ycanth (cantharidin), for people aged 2 and older. Molluscum contagiosum causes itchy bumps, is transmitted through skin-to-skin contact and is most common among children 10 years and younger.
Only healthcare providers can administer the product, and the approved regimen directs providers to apply the topical solution on the bumps every 3 weeks as needed.
In a trial, 13 percent of study participants who received a placebo saw their bumps disappear after 12 weeks, compared to 54 percent of those who received Ycanth.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
